J P Morgan Chase & Co reaffirmed their neutral rating on shares of Novartis AG (NYSE:NVS) in a research note published on Thursday morning.
A number of other research firms also recently weighed in on NVS. Jefferies Group LLC reiterated a buy rating on shares of Novartis AG in a research report on Sunday, October 16th. TheStreet downgraded Novartis AG from a buy rating to a hold rating in a research report on Wednesday, September 28th. Zacks Investment Research downgraded Novartis AG from a hold rating to a sell rating in a research report on Wednesday, September 21st. Berenberg Bank downgraded Novartis AG from a buy rating to a hold rating in a research report on Tuesday, January 17th. Finally, Credit Suisse Group downgraded Novartis AG from an outperform rating to a neutral rating in a research report on Wednesday, January 11th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $85.18.
Shares of Novartis AG (NYSE:NVS) traded up 1.2051% during mid-day trading on Thursday, reaching $70.8739. The company had a trading volume of 820,074 shares. The company has a market cap of $168.36 billion, a price-to-earnings ratio of 24.9908 and a beta of 0.68. Novartis AG has a 52-week low of $66.93 and a 52-week high of $83.58. The firm’s 50-day moving average price is $71.56 and its 200 day moving average price is $76.20.
Novartis AG (NYSE:NVS) last released its earnings results on Wednesday, January 25th. The company reported $1.12 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.12. The firm earned $12.32 billion during the quarter, compared to the consensus estimate of $12.34 billion. Novartis AG had a return on equity of 15.25% and a net margin of 13.98%. The company’s revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.14 EPS. Equities analysts expect that Novartis AG will post $4.71 EPS for the current year.
A number of institutional investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company bought a new stake in shares of Novartis AG during the third quarter valued at $304,776,000. CGOV Asset Management bought a new stake in shares of Novartis AG during the third quarter valued at $82,650,000. Parnassus Investments CA boosted its stake in shares of Novartis AG by 22.9% in the third quarter. Parnassus Investments CA now owns 4,278,005 shares of the company’s stock valued at $337,791,000 after buying an additional 796,109 shares during the last quarter. Aristotle Capital Management LLC boosted its stake in shares of Novartis AG by 31.9% in the second quarter. Aristotle Capital Management LLC now owns 2,736,946 shares of the company’s stock valued at $225,825,000 after buying an additional 662,285 shares during the last quarter. Finally, FMR LLC boosted its stake in shares of Novartis AG by 65.6% in the second quarter. FMR LLC now owns 1,208,384 shares of the company’s stock valued at $99,704,000 after buying an additional 478,679 shares during the last quarter. 9.84% of the stock is owned by institutional investors and hedge funds.
Novartis AG Company Profile
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.